Today, CADTH has issued final recommendations for:
tafamidis (Vyndaqel)
Indications: transthyretin-mediated amyloidosisRecommendation: Reimburse with clinical criteria and/or conditions
For more information
A new project on Rituximab to Treat Primary Membranous Nephropathy is now available for feedback from all interested stakeholders.
Rituximab to Treat Primary Membranous Nephropathy
Call for Feedback: 2020-02-13Feedback Due By: 2020-02-28Consultation Document: Proposed Project ScopeProduct Type:…
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.
See Pharmaceutical Reviews Update – Issue 13 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include:
New consolidated document for pCODR procedures and guidelines
Clarifications regarding economic submission requirements
Update for patients and…
Today, CADTH has issued final recommendations for:
upadacitinib (Rinvoq)
Indications: Arthritis, RheumatoidRecommendation: Reimburse with clinical criteria and/or conditions
For more information
Today, CADTH has issued final recommendations for:
Lorlatinib (Lorbrena) NSCLC
Funding Request: For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on: crizotinib and at least one other ALK inhibitor,…
Connect with Canadian and international experts in the objective assessment and evaluation of health technologies this April in Toronto, Ontario. We have added an additional full day of thought-provoking and interactive workshops to the program for a total of four days of education, information…
Today, CADTH has issued final recommendations for:
Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC)
Funding Request: For the adjuvant treatment of patients with HER2-positive early breast cancer, who have residual disease, after pre-operative systemic treatment. KADCYLA should be…
Today, CADTH has issued final recommendations for:
glucagon (Baqsimi)
Indications: Severe hypoglycemic reactionsRecommendation: Reimburse with clinical criteria and/or conditions
For more information
Today, CADTH has issued final recommendations for:
Nerlynx for Hormone Receptor-Positive Breast Cancer
Funding Request: For patients with HER2-positive, hormone receptor-positive breast (HR-positive) cancer who have completed adjuvant trastuzumab-based therapy within the past 12 months.…
Today, CADTH has issued final recommendations for:
inotersen (Tegsedi)
Indications: hereditary transthyretin amyloidosisRecommendation: Reimburse with clinical criteria and/or conditions
For more information
See Pharmaceutical Reviews Update – Issue 12 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include:
A new process for the submission and review of cell and gene therapies
Updated guidelines on fees for CADTH pharmaceutical reviews
Pending…